EGRIFTA WR begins here with a US FDA medicine identity.
Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.
Resolve the exact identity of EGRIFTA WR through Current EGRIFTA WR prescribing information from National Library of Medicine, DailyMed. Then search Lists of authorized medicinal products from Swissmedic for the destination product record and Guideline on medicines and the Internet from Swissmedic for the seller, establishment, or supply route in Switzerland. A match in one record does not replace the other two checks.
No. A page using the name EGRIFTA WR, local currency, a domestic delivery claim, or a familiar package image is only a lead. EGRIFTA WR is an FDA-approved US tesamorelin prescription product with an exact application, presentation, indication, label, and regulated supply chain. The European Egrifta marketing-authorisation application was withdrawn in 2012. Neither record authenticates research vials, compounded preparations, imported packages, or seller claims, and neither establishes current authorization or supply in another jurisdiction. For Switzerland, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.
Primary identity source: Current EGRIFTA WR prescribing information / National Library of Medicine, DailyMed ↗A credible result must keep these separate. The official links answer different questions and should be checked in sequence.
Current EGRIFTA WR prescribing information is maintained by National Library of Medicine, DailyMed. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Current EGRIFTA WR prescribing information ↗Lists of authorized medicinal products is maintained by Swissmedic. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Lists of authorized medicinal products ↗Guideline on medicines and the Internet is maintained by Swissmedic. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Guideline on medicines and the Internet ↗Swiss medicine authorization and online dispensing are different checks. Swissmedic publishes current authorized-product information, while mail-order dispensing involves legal conditions and cantonal licensing that a foreign seller claim cannot establish.
The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.
Use Swissmedic's current lists and product-information platform to match the exact medicine, pack, authorization holder, and status instead of extrapolating from an active-substance name.
Read Swissmedic's internet-medicine guidance and verify the relevant cantonal mail-order licence. A Swiss-looking domain or address is not evidence of that permission.
Import conditions, a customs outcome, and local licensed dispensing are different routes. Record which one an offer claims before comparing price or availability.
Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.